HH102
-
Ephin, the ligand of the Eph receptor (EPHB3), is united to EPHB3 and induces oligomerization of EPHB3, leading to phosphorylation of EPHB3 residues and activating phosphorylation of signaling proteins under the EPHB3 (Ras-GAP, PI3K, Ephexin, Src, SHP2, JAK). This plays a role in causing cell proliferation / migration / adhesion and negatively regulating the nervous system.
The HH102 EPHB3 antibody is specifically united to the epitope of the EPHB3 protein and competes with Ephrin to inhibit the signaling pathway caused by activated EPHB3. This allows useful application as a treatment for general cancer, resistant cancer, recurrent cancer, or metastatic cancer.
Video instruction
Antibody drug
| Project | Indication | Hit | Lead | Lead Optimization |
Candidate | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|---|---|
| HH102 | Solid Cancer |